Chongqing Zhifei Biological Products Co 2024 ne kadar temettü ödüyor?
Kasım 2024 itibarıyla Chongqing Zhifei Biological Products Co, son 12 ay içinde hisse başına toplam 0,33 CNY tutarında bir temettü ödemiştir. Mevcut Chongqing Zhifei Biological Products Co fiyatı 31,42 CNY olduğunda bu, % 1,06 % oranında bir temettü getirisine karşılık gelir. Yılda kez temettü ödenmektedir.
1,06 % Temettü Verimi | = | 0,33 CNY Temettü | 31,42 CNY Hisse Senedi Fiyatı |
|
Chongqing Zhifei Biological Products Co temettüsü güvende mi?
Chongqing Zhifei Biological Products Co, 2 yıldır temettüsünü artırıyor.
Son 10 yıl içerisinde Chongqing Zhifei Biological Products Co, yıllık 16,087 artırılmış arttırdı.
5 yıllık sürede arttı, dağıtımını 20,722 oranında artırdı.
Analistler, mevcut mali yıl için 12,250 oranında bir Temettü Artışı bekliyorlar.
Chongqing Zhifei Biological Products Co Aktienanalyse
Chongqing Zhifei Biological Products Co ne yapıyor?
Chongqing Zhifei Biological Products Co Ltd is a Chinese company that was founded in 1998 and is headquartered in Chongqing, China. The company operates in the biotechnology sector and focuses on the research, development, and manufacturing of biological products.
The company initially started in the 1990s as a small laboratory unit of Chongqing Lummy Pharmaceutical Co Ltd, a Chinese pharmaceutical company that mainly produced drugs. In 1998, the company decided to focus on the business of biological products and established Chongqing Zhifei Biological Products Co Ltd.
The company's business model is based on the production of high-quality biopharmaceuticals and medical devices. Zhifei Biological Products offers a wide range of products such as vaccines, blood products, virus tests, medical devices, and diagnostic kits.
The company has four main business fields: vaccines, blood products, test kits, and medical devices. Among vaccines, Zhifei Biological Products offers a range of vaccines for the prevention of infectious diseases such as hepatitis B, diphtheria, tetanus, and pertussis. The blood products manufactured by the company include intravenous immunoglobulins, plasma proteins, and albumin. Test kits include IgG antibody tests and quantitative PCR tests. Additionally, the company also offers a wide range of medical devices including blood collection kits, syringes, and infusion sets.
The company has established itself in China as a trusted and reliable manufacturer of biopharmaceuticals and collaborates closely with various healthcare organizations to promote the prevention and control of infectious diseases. Zhifei Biological Products has also successfully exported its products to other countries and is active in the international market.
In recent years, Zhifei Biological Products has also played a crucial role in the fight against the COVID-19 pandemic. The company, in collaboration with the Chinese military, developed and produced a COVID-19 vaccine in a short period of time. This vaccine has already been approved in countries such as Indonesia and Brazil and is being distributed worldwide.
The company takes pride in not only manufacturing biopharmaceuticals but also contributing to creating a better world. It has a strong corporate culture and constantly promotes innovation and advanced technology. Chongqing Zhifei Biological Products Co Ltd is a key player in the Chinese biotechnology industry and plays an important role in improving global health. Chongqing Zhifei Biological Products Co, Eulerpool.com'da en popüler şirketlerden biridir.Aktiensparpläne, yatırımcıların uzun vadeli olarak servet inşa etmeleri için çekici bir fırsat sunar. Ana avantajlardan biri, sözde Cost-Average-Effekti'dir: Düzenli olarak sabit bir miktarın hisse senetlerine veya hisse senedi fonlarına yatırılmasıyla, fiyatlar düşükken otomatik olarak daha fazla pay alınır ve fiyatlar yüksekken daha az alınır. Bu, zaman içinde hisse başına daha uygun bir ortalama fiyata yol açabilir. Ayrıca, Aktiensparpläne, küçük miktarlarla bile pahalı hisselere erişim sağlayarak küçük yatırımcılara da kapılarını açar. Düzenli yatırım, ayrıca disiplinli bir yatırım stratejisini teşvik eder ve impulsif alım veya satım gibi duygusal kararları engellemeye yardımcı olur. Bunun ötesinde, yatırımcılar hisselerin potansiyel değer artışından ve yeniden yatırılabilecek temettü dağıtımlarından faydalanır, bu da bileşik faiz etkisini ve böylece yatırılan sermayenin büyümesini artırır.